Latest Conference Articles

Carel B. Hoyng, MD, discusses his presenation regarding macula dystrophies, including Stargardt disease, Best disease, X-linked retinoschisis, and the peripherin-2 (PRPH2) gene.

José-Alain Sahel, MD, explains how optogenetics involves artificial photoreceptors from specific retinal cells to restore vision.

Jennifer Sun, MD, MPH, explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).

The new virtual conference will debut on Sept. 18, and can help young ophthalmologists solve the small problems before they become bigger problems.

George O. Waring IV, MD, FACS, discusses the latest results from the GEMINI 1 clinical trial of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.

Steven Greenstein, MD, reports on the 10-year postop data from an epi-off corneal collagen cross-linking treatment in keratoconus and ectasia patients.

COO JD Schaub provides an overview of how RVL Pharmaceuticals has shifted toward becoming an ocular aesthetics company, with the sole purpose to fully focus on UPNEEQ®.

Michael Rivers, MD, discusses the impact of Aetna's new policy requiring prior authorization for cataract surgery on ophthalmologists, their workflow, and patients.

The American Academy of Ophthalmology issued a guidance this week requiring all in-person attendees at its annual meeting Nov. 12-15 in New Orleans to show proof of COVID-19 vaccination.

The American Society of Retina Specialists is gearing up for its 39th annual scientific meeting Oct. 8-12 at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas.

Michael Rivers, MD, discusses how Modernizing Medicine's latest updates to its electronic health records EMA® system benefits both ophthalmologists and optometrists.

Michael Rivers, MD, discusses the impact of Aetna's new policy requiring prior authorization for cataract surgery on ophthalmologists, their workflow, and patients.

Edward Holland, MD, discusses Aurion Biotech's investigation of an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.

Edward Manche, MD, discusses results from his presentation regarding outcomes of corneal crosslinking keratoconus in a pediatric population.

Region may have world’s highest rate, investigators say.

Investigators from various companies described their diagnostic offerings at the Glaucoma Research Foundation’s 2021 New Horizons Forum.

Ed Hu, MD, PhD, shares highlights from his paper analyzing three years' worth of his own postop data on comparative lens rotations in toric IOL platforms.

Mitch Shultz, MD, speaks on the capabilities of a cloud-based database system to look at energy-fluid metrics, provide surgeons with the capacity to refine procedures and give patients better outcomes.

Elizabeth Yeu, MD, shares results from the Saturn 1 pivotal phase 2b3 trial evaluating the safety and efficacy of TP03 for the treatment of patients diagnosed with Demodex blepharitis.

Eric Donnenfeld, MD, presents results of the year-long Grail Study demonstrating the safety and performance of the Juvene IOL from LensGen Inc.

Mitchell A. Jackson, MD, presents details of a retrospective review of dexamethasone intraocular suspension 9%, including reduced postoperative inflammation.

Steven Greenstein, MD, reports on results of epi-off corneal collagen cross-linking treatment in keratoconus and ectasia patients 10 years after undergoing laser refractive surgery.

Colman R. Kraff, MD, shares highlights of a study evaluating the safety and efficacy of the use of the iDesign 2.0 Refractive Studio for the treatment of patients with hyperopia and myopia.

Eric Donnenfeld, MD, highlights study results exhibiting risuteganib as a potential treatment option for dry eye disease.

Hisaharu Suzuki, MD, PhD, provides insight on how a handpiece maintains the anterior chamber stability even when occlusion occurs, suggesting its usefulness for a safe and efficient surgery.

Kathryn M. Hatch, MD, details how collagen CXL is evolving with the goals of reducing complications and actually improving visual acuity.